EYPT Research | Milton Maxwell

EYPT

EyePoint, Inc.

16.93

+0.53+3.23%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

1.40B

P/E (TTM)

Basic EPS (TTM)

-3.00

Dividend Yield

Recent Filings

8-K

12/8/25Dec 8, 2025

8-K

11/19/25Nov 19, 2025

8-K

11/5/25Nov 5, 2025

8-K

Phase 3 DME program launches

10/14/25Oct 14, 2025

EyePoint Pharmaceuticals announced its Phase 3 program for DURAVYU in diabetic macular edema, with first patient dosing set for Q1 2026 following FDA alignment on a non-inferiority pathway versus aflibercept. New preclinical data reveals vorolanib's dual inhibition of VEGF and IL-6-mediated inflammation, bolstering Phase 2 VERONA results that showed rapid vision gains and reduced treatment burden. This multi-mechanism approach targets DME's vascular and inflammatory drivers. Cash stands at $200M, funding into 2027.

10-Q

Q2 FY2025 results

8/7/25Aug 7, 2025

EyePoint Pharmaceuticals posted Q2 revenue of $5.3 million, down 44% year-over-year from $9.5 million, driven by lower license recognition from the ANI YUTIQ deal and no product sales, though YTD revenue jumped 41% to $29.8 million thanks to $12.7 million in royalty income from the terminated SWK agreement. R&D expenses surged 86% to $55.5 million, fueled by Phase 3 trials for DURAVYU in wet AMD, pushing operating loss to $62.2 million (up 80% y/y) and net loss to $59.4 million, or $0.85 per diluted share on 69.9 million shares. Cash burn intensified with $115.7 million used in operations, leaving $255.7 million in cash and marketable securities to fund into 2027. Enrollment wrapped in both LUGANO and LUCIA trials. Cash stretches far. Yet regulatory hurdles in retinal trials loom large.

About

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

CEO

Dr. Jay S. Duker M.D.

IPO

1/27/2005

Website

https://eyepoint.bio

Employees

165

Sector

Healthcare

Industry

Biotechnology